Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial
Mené sur 123 patients atteints d'un cancer colorectal métastatique et réfractaire (durée médiane de suivi : 1,18 an), cet essai multicentrique de phase II compare l'efficacité et la toxicité de deux stratégies thérapeutiques utilisant le régorafénib (dosage standard et escalade de doses)
A growing number of patients with unresectable metastatic colorectal cancer can receive several lines of chemotherapy enabling maintenance of performance status and quality of life over long treatment periods. Even in the chemotherapy refractory setting (ie, after progression on fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic drugs and—if feasible in terms of RAS and BRAF status—antibodies targeting EGFR), reasonable and licensed treatment options such as regorafenib and TAS-102 are available. Regorafenib, an oral multitargeted kinase inhibitor, was shown to improve survival in the pivotal CORRECT 1 and CONCUR 2 studies in both white and Asian patients. However, its use is limited by considerable toxicities such as hypertension, hand-foot skin reaction, fatigue, diarrhoea, and liver toxicity.
The Lancet Oncology , commentaire, 2018